Detalhe da pesquisa
1.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
Cell;
187(10): 2536-2556.e30, 2024 May 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38653237
2.
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
Clin Chem;
70(2): 434-443, 2024 02 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38069911
3.
Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
Ann Surg Oncol;
31(4): 2713-2726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38158497
4.
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma.
JCO Precis Oncol;
8: e2300368, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38237100
5.
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
JAAD Int;
15: 105-114, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38500872
6.
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
bioRxiv;
2024 Mar 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38405985
7.
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
JAMA Netw Open;
6(8): e2327145, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37535354
8.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Eur J Cancer;
194: 113354, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37827067
9.
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.
bioRxiv;
2023 Nov 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37790460
10.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
bioRxiv;
2023 Oct 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37961514
11.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine;
65: 102290, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37965433
12.
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
J Clin Oncol;
40(1): 12-23, 2022 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34752147
13.
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
JAMA Oncol;
7(5): 744-748, 2021 05 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33764387
14.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine;
71: 102564, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38572079